A cellular epigenetic classification system for glioblastoma
Neuro-Oncology · 2026
DOI: 10.1093/neuonc/noaf299 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Dana Silverbush und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, University of Pennsylvania, -Philadelphia. Hauptthemen laut MEDLINE: Glioblastoma, DNA Methylation, Brain Neoplasms, Epigenesis, Genetic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH, Princess Margaret Cancer Foundation.
Abstract (Originalsprache)
Background
Cellular heterogeneity is a defining feature of glioblastoma (GBM), shaping tumor progression and therapeutic response. While single-cell profiling resolves this heterogeneity, it remains impractical for large-cohort studies and clinical implementation. Conversely, DNA methylation-based classification is widely used for GBM diagnostics but does not provide cellular resolution.
Methods
We introduce a hierarchical non-negative matrix factorization approach (ITHresolveGBM) to deconvolute bulk DNA methylation profiles, inferring the abundance of glial, immune, and neuronal cells of the microenvironment, and further distinguishing differentiation states of malignant cells.
Results
Using ITHresolveGBM, we find that low tumor cell content impairs methylation-based classification, most notably linking the mesenchymal subtype with high immune cell infiltration. By integrating multi-omic single-cell data, we show that epigenetic deconvolution captures a malignant differentiation continuum ranging from stem-like to more differentiated tumors. This continuum aligns prior GBM classification systems and is associated with distinct molecular drivers (eg, PDGFRA, TP53, EGFR) and survival outcomes.
Conclusions
Our framework reconciles DNA methylation- and RNA-based classification systems and provides a blueprint for unifying bulk tumor profiles with single-cell biology, thereby refining molecular stratification and enhancing GBM diagnostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, University of Pennsylvania, -Philadelphia.
- Department of Neurosurgery, University of Pennsylvania, Philadelphia.
- Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia.
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston.
- Division of Hematology/Oncology, Boston -Children's Hospital, Boston.
- Broad Institute of MIT and Harvard, Cambridge.
ORCID-Profile: Dana Silverbush, Mario L Suvà, Volker Hovestadt
Förderung
- NCI NIH HHS
- NIH
- Princess Margaret Cancer Foundation
- Ontario Institute for Cancer Research Investigator Award
- MGH Research Scholars Award
- NCI
Zitieren
APA
Silverbush, D., Jürgensen, L., Freeburg, N. F., Pooley, C. S., Boniolo, F., Gaiti, F., Suvà, M. L., & Hovestadt, V. (2026). A cellular epigenetic classification system for glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf299
Vancouver
Silverbush D, Jürgensen L, Freeburg NF, Pooley CS, Boniolo F, Gaiti F, et al. A cellular epigenetic classification system for glioblastoma. Neuro-Oncology. 2026. doi:10.1093/neuonc/noaf299
BibTeX
@article{Silverbush2026,
author = {Silverbush, Dana and Jürgensen, Liv and Freeburg, Nelson F and Pooley, Channing S and Boniolo, Fabio and Gaiti, Federico and Suvà, Mario L and Hovestadt, Volker},
title = {A cellular epigenetic classification system for glioblastoma},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noaf299}
}
EUVIMED